Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Amyloid Fibrils03:03

Amyloid Fibrils

6.8K
6.8K
Amyloid Fibrils03:03

Amyloid Fibrils

12.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.2K
Neural Regulation01:37

Neural Regulation

43.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and long-term outcomes of children with confirmed focal cortical dysplasia type 1 after epilepsy surgery: A population-based study.

Epilepsia open·2026
Same author

Genetic analysis of limbic-predominant age-related TDP-43 encephalopathy neuropathologic change in a population-based cohort of the oldest old.

Brain communications·2026
Same author

Robust immunohistochemical detection of α-synuclein, tau and amyloid-β in human brain tissue archived for up to 78 years.

Free neuropathology·2026
Same author

The prevalence of Lewy body pathology across nine international community-based cohorts.

Brain : a journal of neurology·2026
Same author

Carotid arteries in cerebral small vessel disease and dementia.

Acta neuropathologica communications·2026
Same author

High vulnerability of medial prefrontal pyramidal neurons in post-stroke, vascular, Alzheimer's disease, and aging-related dementias.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Mar 2, 2026

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K

Amygdala α-Synuclein Pathology in the Population-Based Vantaa 85+ Study.

Anna Raunio1, Liisa Myllykangas1, Mia Kero1

  • 1Department of Pathology, University of Helsinkiand Helsinki University Hospital, Helsinki, Finland.

Journal of Alzheimer'S Disease : JAD
|May 10, 2017
PubMed
Summary

Lewy-related pathology (LRP) affects one-third of individuals in the amygdala. Amygdala LRP is linked to dementia but requires pathology in other brain regions to be an independent risk factor.

Keywords:
80 and overAlzheimer’s diseaseLewy body diseaseLewy-related pathologyagedamygdalaamygdala-predominantpopulation-based studyα-synuclein

More Related Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

11.4K

Related Experiment Videos

Last Updated: Mar 2, 2026

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

11.4K

Area of Science:

  • Neuropathology
  • Neurodegenerative Diseases
  • Aging Research

Background:

  • Lewy-related pathology (LRP) is a hallmark of Lewy body dementia (DLB).
  • The amygdala's role in LRP and its association with dementia subtypes requires further investigation.
  • Population-based studies are crucial for understanding the prevalence of neurodegenerative pathologies.

Purpose of the Study:

  • To determine the frequency of Lewy-related pathology (LRP) in the amygdala.
  • To compare amygdala LRP with LRP and Alzheimer's disease (AD) pathology in other brain regions.
  • To assess the association of amygdala LRP with dementia and its independence as a risk factor.

Main Methods:

  • Analysis of amygdala samples (N=304) from the population-based Vantaa 85+ study.
  • Immunostaining using two alpha-synuclein antibodies (clone 42 and clone 5G4).
  • Comparison of amygdala LRP data with previously analyzed pathologies in other brain regions.

Main Results:

  • Amygdala LRP was detected in 33% of subjects.
  • Pure AD subjects showed 5% amygdala LRP, while pure DLB subjects had 85% amygdala LRP.
  • Amygdala LRP was associated with dementia, but this association was dependent on LRP in other brain regions, not an independent factor.

Conclusions:

  • Lewy-related pathology in the amygdala is common but not an independent predictor of dementia.
  • The presence of LRP in other brain regions is necessary for amygdala LRP to be associated with dementia.
  • Amygdala-predominant LRP is a rare and heterogeneous finding.